AURORA, ON, April 7 /PRNewswire-FirstCall/ - Helix BioPharma Corp.
Helix BioPharma Corp. today announced that the board of directors has increased the authorized number of directors from six to seven and has appointed Mr. W. Thomas Hodgson as director to fill the newly created position. Mr. Hodgson will also serve as chair of the three member Audit Committee, replacing Mr. Jack Kay who previously held the position.
Mr. Hodgson is currently senior partner and chairman of Greenbrook Capital Partners and acts as an advisor to the chairman of Magna Entertainment Corp. Mr. Hodgson’s prior roles include senior positions with Canadian financial institutions and U.K. based companies.
Donald Segal, chief executive officer of Helix BioPharma, said, “Tom’s diverse professional background and capital markets experience will be an invaluable resource to the board. In addition, his extensive knowledge of complex financial matters makes him ideally suited to chair our audit committee. We look forward to his contributions.”
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol “HBP” and quoted on the Frankfurt, Berlin, Munich and Stuttgart Stock Exchanges under the same symbol.
CONTACT: Investor Relations: Christina Bessant, The Equicom Group Inc.,
Tel: (416) 815-0700 ext. 269, (800) 385-5451, Fax: (416) 815-0080, Email:
cbessant@equicomgroup.com; Media Relations: David Schull, Russo Partners
LLC, Tel: (212) 845-4271, Fax: (212) 845-4260, Email:
David.Schull@russopartnersllc.com; www.russopartnersllc.com
